Browse by author
Lookup NU author(s): Dr Carlos Celis Morales, Dr Katherine Livingstone, Professor Lorraine Brennan, Professor John Mathers
This is the authors' accepted manuscript of an article that has been published in its final definitive form by American Society for Nutrition , 2017.
For re-use rights please refer to the publisher's terms and conditions.
Background: There has been limited evidence about whether genotype-tailored advice provides extra benefits in reducing obesity-related traits compared with the benefits of conventional one-size-fits-all advice. Objective: We determined whether the disclosure of information on fat-mass and obesity-associated (FTO) genotype risk had a greater effect on a reduction of obesity-related traits in risk carriers than in nonrisk carriers across different levels of personalized nutrition. Design: A total of 683 participants (women: 51%; age range: 18–73 y) from the Food4Me randomized controlled trial were included in this analysis. Participants were randomly assigned to 4 intervention arms as follows: level 0, control group; level 1, dietary group; level 2, phenotype group; and level 3, genetic group. FTO (single nucleotide polymorphism rs9939609) was genotyped at baseline in all participants, but only subjects who were randomly assigned to level 3 were informed about their genotypes. Level 3 participants were stratified into risk carriers (AA/AT) and nonrisk carriers (TT) of the FTO gene for analyses. Height, weight, and waist circumference (WC) were self-measured and reported at baseline and months 3 and 6. Results: Changes in adiposity markers were greater in participants who were informed that they carried the FTO risk allele (level 3 AT/AA carriers) than in the nonpersonalized group (level 0) but not in the other personalized groups (level 1 and 2). Mean reductions in weight and WC at month 6 were greater for FTO risk carriers than for noncarriers in the level 3 group [−2.28 kg (95% CI: −3.06, −1.48 kg) compared with −1.99 kg (−2.19, −0.19 kg), respectively (P = 0.037); and −4.34 cm (−5.63, −3.08 cm) compared with −1.99 cm (−4.04, −0.05 cm), respectively, (P = 0.048)]. Conclusions: There are greater body weight and WC reductions in risk carriers than in nonrisk carriers of the FTO gene. This trial was registered at clinicaltrials.gov as NCT01530139.
Author(s): Celis-Morales C, Marsaux CFM, Livingstone KM, Navas-Carretero S, San-Cristobal R, Fallaize R, Macready AL, O'Donovan C, Woolhead C, Forster H, Kolossa S, Daniel H, Moschonis G, Mavrogianni C, Manios Y, Surwillo A, Traczyk I, Drevon CA, Grimaldi K, Bouwman J, Gibney MJ, Walsh MC, Gibney ER, Brennan L, Lovegrove JA, Martinez JA, Saris WHM, Mathers JC
Publication type: Article
Publication status: Published
Journal: The American Journal of Clinical Nutrition
Year: 2017
Volume: 105
Issue: 5
Pages: 1204-1213
Print publication date: 01/05/2017
Online publication date: 05/04/2017
Acceptance date: 03/03/2017
Date deposited: 26/04/2017
ISSN (print): 0002-9165
ISSN (electronic): 1938-3207
Publisher: American Society for Nutrition
URL: https://doi.org/10.3945/ajcn.116.145680
DOI: 10.3945/ajcn.116.145680
PubMed id: 28381478
Altmetrics provided by Altmetric
